PLoS neglected tropical diseases · 2026
Effect of the time of day for vaccination on the immune response to Ebola Virus Disease vaccines: A modeling study from PREVAC randomized trial.
СтатьяРандомизированное исследованиеКлиническое исследование II фазыНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kpetigo Ange-Marie D, Alexandre Marie, Camara Aboubacar, Beavogui Abdoul, Doumbia Seydou, Kieh Mark, Leigh Bailah, Sow Samba, Wittkop Linda, Soutthiphong Anne-Aygline, Berry Irina Maljkovic, Fleck Suzanne, Akoo Pauline, Hamze Benjamin, Watson-Jones Deborah, Kuhn Jens H, Greenwood Brian, Richert Laura, Yazdanpanah Yazdan, Lévy Yves, Thiébaut Rodolphe, Prague Mélanie, PREVAC Study Team, Lhomme Edouard
Аннотация
BACKGROUND: Emerging evidence suggests that the time in the day of vaccination may influence post-vaccination immunogenicity. The main objective of this study was to assess the association between the time of vaccination and the anti-EBOV GP1,2 IgG antibody response at 12 mo following vaccination against Ebola virus disease (EVD).
METHODOLOGY/PRINCIPAL FINDINGS: This study utilized data from a randomized, double-blind, placebo-controlled international phase 2b clinical trial (PREVAC) evaluating the immunogenicity of three vaccination strategies against Ebola virus disease (rVSVΔG-ZEBOV-GP one and two doses, and Ad26.ZEBOV/MVA-BN-Filo) in 1,859 healthy Western Africans. In the overall population, we measured a statistically significant association between the time of day of first vaccination and anti-Ebola virus immunoglobulin G levels at 12 mo (p = 0.02). The magnitude of this association was small, participants vaccinated at 1600 h were estimated to have 1-7% lower antibody levels at 12 mo compared to those vaccinated at 1000 h.
CONCLUSIONS/SIGNIFICANCE: An effect of the time of first vaccination on the antibody responses was found but remains modest and unlikely to impact the EVD vaccine effectiveness.
CLINICAL TRIALS REGISTRATION: ClinicalTrials.gov registration: NCT02876328.
METHODOLOGY/PRINCIPAL FINDINGS: This study utilized data from a randomized, double-blind, placebo-controlled international phase 2b clinical trial (PREVAC) evaluating the immunogenicity of three vaccination strategies against Ebola virus disease (rVSVΔG-ZEBOV-GP one and two doses, and Ad26.ZEBOV/MVA-BN-Filo) in 1,859 healthy Western Africans. In the overall population, we measured a statistically significant association between the time of day of first vaccination and anti-Ebola virus immunoglobulin G levels at 12 mo (p = 0.02). The magnitude of this association was small, participants vaccinated at 1600 h were estimated to have 1-7% lower antibody levels at 12 mo compared to those vaccinated at 1000 h.
CONCLUSIONS/SIGNIFICANCE: An effect of the time of first vaccination on the antibody responses was found but remains modest and unlikely to impact the EVD vaccine effectiveness.
CLINICAL TRIALS REGISTRATION: ClinicalTrials.gov registration: NCT02876328.